Gyre Therapeutics, Inc. Payments to Acquire Intangible Assets
Gyre Therapeutics, Inc. (GYRE) reported Payments to Acquire Intangible Assets of $1.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireIntangibleAssets · last filed 2026-08-07
- Gyre Therapeutics, Inc. payments to acquire intangible assets for the quarter ending 2026-06-30 was $1.02M, a 4352.17% increase year-over-year.
- Gyre Therapeutics, Inc. payments to acquire intangible assets for the quarter ending 2026-03-31 was $5.00K, a 99.28% decline year-over-year.
- Gyre Therapeutics, Inc. payments to acquire intangible assets for the quarter ending 2025-12-31 was -$4.00K, a 100.49% decline year-over-year.
- Gyre Therapeutics, Inc. payments to acquire intangible assets for the quarter ending 2025-09-30 was $15.00K.
- Gyre Therapeutics, Inc. payments to acquire intangible assets for fiscal 2025 was $733.00K, a 9.84% decline from fiscal 2024.
- Gyre Therapeutics, Inc. payments to acquire intangible assets for fiscal 2024 was $813.00K, a 1078.26% increase from fiscal 2023.
- Gyre Therapeutics, Inc. payments to acquire intangible assets for fiscal 2023 was $69.00K, a 430.77% increase from fiscal 2022.
- Gyre Therapeutics, Inc. payments to acquire intangible assets for fiscal 2022 was $13.00K.
| Period end | Payments to Acquire Intangible Assets 3 month | Payments to Acquire Intangible Assets 6 month | Payments to Acquire Intangible Assets 9 month | Payments to Acquire Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.03M 10-Q · filed 2026-08-07 | $1.02M derived: sum of 3 quarters · filed 2026-08-07 | $1.04M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $5.00K 10-Q · filed 2026-05-08 | $1.00K derived: sum of 2 quarters · filed 2026-05-08 | $16.00K derived: sum of 3 quarters · filed 2026-05-08 | $39.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $11.00K derived: sum of 2 quarters · filed 2026-03-13 | $34.00K derived: sum of 3 quarters · filed 2026-08-07 | $733.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $38.00K derived: sum of 2 quarters · filed 2026-08-07 | $737.00K 10-Q · filed 2025-11-07 | $1.55M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $722.00K 10-Q · filed 2026-08-07 | $1.53M derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-03-31 | $699.00K 10-Q · filed 2026-05-08 | $1.51M derived: sum of 2 quarters · filed 2026-05-08 | ||
| 2024-12-31 | $810.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $813.00K 10-K · filed 2026-03-13 | ||
| 2024-09-30 | $3.00K 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $3.00K derived: sum of 2 quarters · filed 2025-03-17 | $4.00K derived: sum of 3 quarters · filed 2025-03-17 | $69.00K 10-K · filed 2025-03-17 |
| 2023-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.00K derived: sum of 2 quarters · filed 2024-11-13 | $68.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $66.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $65.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $13.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |